TCT 272: Escalation of Mechanical Circulatory Support in non-comatose Patients with STEMI-related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Edwards Lifesciences; Abiomed; Boston Scientific Corporation; Bristol-Myers Squibb; Medtronic; B. Braun; Biotronik; Inari Medical</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Amgen; Shockwave Medical</li><li>Grant Support/Research Contract - Abiomed; Boston Scientific Corporation</li></ul>